Lori Freedman - 04 Jun 2025 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Role: Chief Admin. and Legal Officer
Signature: /s/ William R. Kolb, Attorney-in-Fact
Issuer symbol: ORGO
Transactions as of: 04 Jun 2025
Net transactions value: +$725,290
Form type: 4
Filing time: 06 Jun 2025, 17:44:18 UTC
Previous filing: 21 Feb 2025
Next filing: 18 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Freedman Lori	Chief Admin. and Legal Officer	C/O ORGANOGENESIS HOLDINGS INC., 85 DAN ROAD, CANTON	/s/ William R. Kolb, Attorney-in-Fact	06 Jun 2025	0001410291

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ORGO	Class A Common Stock	Purchase	$284,716	+100,863	+17%	$2.82	695,058	04 Jun 2025	Direct	F1
transaction	ORGO	Class A Common Stock	Purchase	$413,625	+142,379	+20%	$2.91	837,437	05 Jun 2025	Direct	F2
transaction	ORGO	Class A Common Stock	Purchase	$26,949	+9,022	+1.1%	$2.99	846,459	06 Jun 2025	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.74 to $2.875, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2	The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.815 to $2.98, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3	The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.945 to $3.00, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4.